InnoCare Pharma Limited (HKG: 9969)

InnoCare Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	6,948	8,287	8,743	5,929	3,970	2,292
Short-Term Investments	-	-	313.29	-	-	-
Trading Asset Securities	350.41	-	-	317.06	-	80.35
Cash & Short-Term Investments	7,299	8,287	9,056	6,246	3,970	2,372
Cash Growth	-16.50%	-8.49%	45.00%	57.34%	67.35%	15.96%
Accounts Receivable	280.68	276.38	127.82	45.27	0.15	0.04
Other Receivables	0.27	31.34	0.99	62.27	78.1	23.39
Receivables	280.94	307.71	128.82	107.55	78.25	23.43
Inventory	118.38	119.09	65.32	9.92	1.88	-
Other Current Assets	372.58	51.38	49.37	53.87	42.46	13.2
Total Current Assets	8,071	8,765	9,300	6,417	4,092	2,409
Property, Plant & Equipment	845.5	798.5	681.5	566.08	403.13	134.79
Long-Term Investments	4.12	5.66	11.71	326.1	1.16	1.16
Goodwill	3.12	3.12	3.12	3.13	3.13	3.13
Other Intangible Assets	261.17	266.03	273.14	34.17	37.02	0.43
Long-Term Deferred Charges	34.4	33.3	39.82	-	-	36.58
Other Long-Term Assets	457.23	48.06	19.77	50.95	1.05	30.86
Total Assets	9,676	9,920	10,329	7,398	4,538	2,616
Accounts Payable	117.24	134.9	118.6	84.6	5.52	8.2
Accrued Expenses	89.49	100.08	119.46	97.5	50.21	10.07
Short-Term Debt	1,280	-	-	-	-	9.1
Current Portion of Long-Term Debt	-	1,251	1,197	-	-	-
Current Portion of Leases	34.18	28.23	20.11	20.34	6.83	6.2
Current Unearned Revenue	-	-	4.24	19.48	6.65	0.65
Other Current Liabilities	579.57	567.64	608.09	107.39	35.25	31.46
Total Current Liabilities	2,100	2,082	2,068	329.3	104.45	65.67
Long-Term Debt	327.95	331.88	287.76	1,238	1,150	5,331
Long-Term Leases	39.78	43.65	35.44	47.44	17.17	3.39
Long-Term Unearned Revenue	269.64	281.78	293.58	123.61	100	157.39
Long-Term Deferred Tax Liabilities	-	-	-	-	6.04	6.04
Total Liabilities	2,738	2,739	2,684	1,739	1,377	5,563
Common Stock	0.02	0.02	0.02	0.02	0.02	0
Additional Paid-In Capital	12,147	12,150	12,082	9,372	6,743	9.34
Retained Earnings	-5,341	-5,080	-4,448	-3,536	-3,544	-3,080
Comprensive Income & Other	113.56	77.23	-36.31	-230.85	-95.05	66.34
Total Common Equity	6,912	7,148	7,597	5,605	3,104	-3,005
Minority Interest	26.75	32.86	47.23	54.36	56.49	56.96
Shareholders' Equity	6,938	7,181	7,644	5,659	3,161	-2,948
Total Liabilities & Equity	9,676	9,920	10,329	7,398	4,538	2,616
Total Debt	1,682	1,655	1,540	1,306	1,174	5,350
Net Cash (Debt)	5,617	6,632	7,516	4,940	2,796	-2,978
Net Cash Growth	-21.51%	-11.76%	52.15%	76.67%	-	-
Net Cash Per Share	3.34	3.89	5.09	3.62	2.89	-12.96
Filing Date Shares Outstanding	1,493	1,763	1,764	1,500	1,289	300.26
Total Common Shares Outstanding	1,493	1,763	1,764	1,500	1,289	300.26
Working Capital	5,970	6,683	7,232	6,088	3,988	2,343
Book Value Per Share	4.63	4.05	4.31	3.74	2.41	-10.01
Tangible Book Value	6,647	6,879	7,321	5,567	3,064	-3,008
Tangible Book Value Per Share	4.45	3.90	4.15	3.71	2.38	-10.02
Buildings	370.06	364.63	224.41	81.04	-	-
Machinery	340.04	302.01	248.14	127.57	13.91	7.51
Construction In Progress	198.58	166.91	197.65	230.72	296.93	44.36
Leasehold Improvements	-	-	-	6.68	1.08	0.05

Source: S&P Capital IQ. Standard template. Financial Sources.